Horizon Discovery Appoints Dr David Smoller as an Executive Director
News Nov 03, 2014
David recently joined Horizon as Chief Business Officer as part of the Company’s recent acquisition of Sage Labs for $48 million (£29 million). David, a successful serial entrepreneur, was previously Chief Executive Officer of Sage Labs, Chief Scientific Officer of Sigma-Aldrich and President of its Research Biotechnology business unit.
Before joining Sigma-Aldrich, David served as President of ProteoPlex, a seed stage spinout focusing on proteomics (acquired by Merck KGaA in 2003), and founded Genome Systems Inc. (acquired by Incyte Genomics in 1996), a company focused on providing the scientific community access to genome project-related technologies.
David has a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He also completed postdoctoral fellowships at Washington University in St. Louis Missouri, and at Monsanto Corporation.
Dr. Ian Gilham, Chairman of Horizon Discovery Group’s Board of Directors, commented: “I would like to welcome David to Horizon’s Board and I am confident that David’s deep experience in identifying and nurturing high value technologies and in building successful life sciences businesses will prove a tremendous asset as Horizon continues to grow.”
Dr David Smoller, Chief Business Officer of Horizon Discovery Group said: “The integration of Sage Labs and Horizon is progressing well and I am delighted to be joining the Horizon Board at this exciting time for the Company.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE